GlassScriptPhysician profile
Tony John
NPI 1366462400
$1,675.82
in general payments reported to CMS, 2019-2025
21 companies · $455 in 2025
The $455 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.13 · 2021: $15.26 · 2022: $362 · 2023: $338 · 2024: $487 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $284.22 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $194.14 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $149.83 | 2022-2025 | |
| Tris Pharma INC | $136.49 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $125.32 | 2019-2024 | |
| Verrica Pharmaceuticals INC. | $112.90 | 2023-2024 | Ycanth |
| Cranial Technologies, INC | $102.44 | 2023-2025 | Doc Band |
| Sobi, INC | $100.74 | 2022-2023 | |
| Sanofi Pasteur INC. | $68.98 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $62.81 | 2021-2024 | Qelbree, Qelbree |
| Seqirus USA INC | $54.56 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Corium, LLC | $52.28 | 2022-2024 | Azstarys |
| Azurity Pharmaceuticals, INC. | $46.66 | 2025 | Alvesco |
| Neos Therapeutics, LP | $34.45 | 2024-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Nestle Healthcare Nutrition INC. | $26.19 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $25.06 | 2024 | |
| Organon LLC | $23.37 | 2025 | Vtama |
| Astrazeneca Pharmaceuticals LP | $21.88 | 2024 | Flumist Quadrivalent |
| Photonicare INC | $18.98 | 2024 | Otosight Middle Ear Scope |
| Alk-Abello, INC | $17.51 | 2025 | Neffy |
| Abbott Laboratories | $17.01 | 2023 | Id Now Instrument |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.